FDA Plans For Soy Health Claims, Pyridoxamine's Use Questioned By CRN, NPA

FDA’s proposed rule to revoke soy protein heart health ignores research supporting the claims and cites evidence that isn't compelling, CRN an NPA say in comments to the agency. CRN also submits comments supporting an ingredient firm's petition asking FDA to remove any uncertainty about the of use of pyridoxamine as a dietary ingredient.

Compliance

FDA’s proposed rule to revoke soy protein label claims for heart health ignores research supporting the claims and relies on less-than-compelling evidence, dietary supplement industry trade groups say in comments to the agency.

In its separate comment on a separate supplement market regulatory issue FDA is considering, one of the groups, the Council...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United States

More from North America